Bladder Cancer

Latest News

Findings from the phase 3 SWOG S1011 trial indicate no significant differences between extended lymphadenectomy vs standard lymphadenectomy in terms of disease-free survival in patients with muscle-invasive breast cancer.
No Improvement in OS With Extended Vs Standard Lymphadenectomy in MIBC

June 6th 2023

Findings from the phase 3 SWOG S1011 trial highlight no significant differences between extended lymphadenectomy vs standard lymphadenectomy in terms of disease-free survival in patients with muscle-invasive breast cancer.

Pembrolizumab in combination with enfortumab vedotin-ejfv demonstrates a manageable safety profile in the treatment of metastatic urothelial carcinoma in the EV-103 trial.
Enfortumab Vedotin Combo Shows Activity in Metastatic Urothelial Carcinoma

June 6th 2023

The overall survival benefit of erdafitinib supports molecular testing of FGFR in all patients with metastatic urothelial carcinoma, according to an expert from University Paris-Saclay in France.
Erdafitinib Improves Survival Vs Chemo in FGFR-Altered Urothelial Cancer

June 5th 2023

Findings from a retrospective analysis highlight no significant differences in metastasis-free survival in patients with muscle-invasive bladder cancer who received radical cystectomy vs trimodality therapy.
Trimodality Therapy Yields Similar Outcomes Vs Radical Cystectomy in MIBC

May 22nd 2023

FDA Declines N-803 Combo Approval in Non-Muscle Invasive Bladder Cancer | Image Credit: © magicmine - stock.adobe.com.
FDA Declines N-803 Combo Approval in Non-Muscle Invasive Bladder Cancer

May 11th 2023

Video Series
Video Interviews
Podcasts
Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

More News